AIM
AIM ImmunoTech·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
AIM fundamentals
AIM ImmunoTech (AIM) released its earnings on Aug 14, 2025: revenue was 25.00K (YoY -50.00%), missed estimates; EPS was -3.68 (YoY -5157.14%), beat estimates.
Revenue / YoY
25.00K
-50.00%
EPS / YoY
-3.68
-5157.14%
Report date
Aug 14, 2025
EPS
Revenue
Revenue & Expenses
AIM has released its 2025 Q2 earnings report, with revenue of 25.00K, reflecting a YoY change of -50.00%, and net profit of -2.79M, showing a YoY change of -52.18%. The Sankey diagram below clearly presents AIM's revenue sources and cost distribution.
Key Indicators
AIM ImmunoTech (AIM) key financial stats and ratios, covering profitability, financial health, and leverage.
AIM ImmunoTech (AIM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
AIM ImmunoTech (AIM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
AIM ImmunoTech (AIM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does AIM ImmunoTech (AIM) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track AIM ImmunoTech (AIM) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What guidance did AIM ImmunoTech's management provide for the next earnings period?What were the key takeaways from AIM ImmunoTech's earnings call?What were the key takeaways from AIM ImmunoTech’s earnings call?What factors drove the changes in AIM ImmunoTech's revenue and profit?Did AIM ImmunoTech beat or miss consensus estimates last quarter?What is AIM ImmunoTech's gross profit margin?What is AIM ImmunoTech's latest dividend and current dividend yield?What is the market's earnings forecast for AIM ImmunoTech next quarter?
